LAVA-1266

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameLAVA-1266
Drug Alias NameLAVA-1266LAVA1266
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLava Therapeutics NV
China Registration ClassN/A

Develop Information

Active CompaniesWorldwide Clinical Trials Pty LtdLava Therapeutics NV
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A